Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
Unternehmens-codePODD
Name des UnternehmensInsulet Corp
IPO-datumMay 15, 2007
Gegründet am2000
CEOMs. Ashley Mcevoy
Anzahl der mitarbeiter3900
WertpapierartOrdinary Share
GeschäftsjahresendeMay 15
Addresse100 Nagog Park
StadtACTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl01720-3440
Telefon19786007000
Websitehttps://www.omnipod.com
Unternehmens-codePODD
IPO-datumMay 15, 2007
Gegründet am2000
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten